First-in-Human, Phase 1/2 Trial to Assess the Safety and Clinical Activity of Subcutaneous GEN3013 (DuoBody®-CD3×CD20) in B-Cell Non-Hodgkin Lymphomas

Published 2020 View Full Article

Authors

Keywords

Journal

BLOOD

Volume 134, Issue Supplement_1, Pages 758-758

Publisher

American Society of Hematology

Online

2020-02-14

DOI

10.1182/blood-2019-121460

Ask authors/readers for more resources

Find the ideal target journal for your manuscript

Explore over 38,000 international journals covering a vast array of academic fields.

Become a Peeref-certified reviewer

The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.

Get Started

BLOOD

Ask authors/readers for more resources

Protocol

Reagent

Reprint

Find the ideal target journal for your manuscript

Become a Peeref-certified reviewer